GRAIL to Present Final Multi-cancer Early Detection Data From the Interventional PATHFINDER Study at ESMO Congress 2022
Final Data From One of the Largest Multi-Cancer Early Detection Studies in an Intended Use Population MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced final results from the interventional PATHFINDER study will be presented at the European Society for Medical Oncology … [Read more…]
